摘要
[目的]评价3种不同方法治疗晚期非小细胞肺癌的疗效。[方法]85例经病理学诊断的晚期肺癌患者随机分为3组,A组(27例)经静脉给药化疗组,B组(30例)单纯支气管动脉灌注化疗组,C组(28例)超选择性支气管动脉栓塞化疗组。3组均采用吉西他滨联合顺铂进行治疗。[结果]近期疗效总有效率56.5%,其中A、B、C3组分别为40.7%(11/27),56.7%(17/30),71.4%穴20/28雪穴P<0.05)。1、2年生存率3组分别为53.8%、30.0%;69.2%、48.2%;83.5%、65.7%,各组间差异有显著性(P<0.05)。不良反应主要为骨髓抑制、胃肠道反应,未出现脊髓损伤等严重并发症。[结论]超选择性支气管动脉栓塞化疗是治疗晚期NSCLC的一种安全有效的方法,其疗效优于静脉注射和单纯支气管动脉灌注化疗。
To evaluate the effect of three different modalities for patients with advanced non-small cell lung cancer (NSCLC).Eight-five patients with advanced NSCLC by pathologically proved were randomly divided into three groups:intravenous chemotherapy group(group A,27cases),bronchial artery infusion chemotherapy group(group B,30 cases),and superselective bronchial artery chemoembolization group (group C,28 cases),Gemcitabin combined with cisplatin were all used in the three groups.The overall response rate was 56.5%,with 40.7%(11/27)in group A,56.7%(17/30)in group B and 71.4%(20/28)in group C(P<0.05). The 1-and 2-year survival rates were 53.8% and 30.0% in group A; 69.2% and 48.2% in group B; 83.5% and 65.7% in group C,respectively,with significant difference(P<0.05). The main side effects were myelosuppression, gastrointestinal reactions.No severe complications such as spinal injury were found.[Conclusion]Superselective bronchial artery chemoembolization is effective and safe for NSCLC,Its response is superior to intravenous chemotherapy and simply bronchial artery infusion.
出处
《中国肿瘤》
CAS
2004年第8期515-516,共2页
China Cancer
关键词
非小细胞肺癌
吉西他滨
顺铂
药物疗法
介入疗法
non-small cell lung cancer
gemcitabine
cisplatin
drug therapy
interventional therapy
